Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.

The Fracture Risk Assessment Tool predictions suggest patients who don’t meet guideline criteria for parathyroidectomy may ...

The FDA has approved datopotamab deruxtecan (Dato-DXd, Datroway, Daiichi Sankyo) for the treatment of patients with ...

Participants on weekly injections of 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks, and 45.3% of participants achieved ≥ 30% weight loss.

Semaglutide and tirzepatide use is rising among patients with rheumatic and musculoskeletal diseases and is linked to meaningful 1-year weight loss, especially in tirzepatide users.

The oral therapy is intended for adults with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis, two fibrotic ...

An early evaluation of 'Swap to Stop' scheme in England shows a 4-week quit rate of 34.3% among recipients of free ...

Emerging evidence suggests some sugar substitutes may affect metabolism, gut microbiome, and cardiovascular health more than ...

Dr Sunnie Kim previews key GI trials highlighting novel bispecific antibodies, dual immunotherapy combinations, KIT ...

The conditional authorization covers adults and children aged 2 years and older with severe or life-threatening ...

A cohort study of births in Brazil found increased hospitalization risk through age 3 after maternal chikungunya; results ...

Pierre de Brémond d’Ars, a French GP who leads the evidence-based medicine group NoFakeMed, tells Medscape’s French edition ...